These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 621427)

  • 21. The role of intrarenal angiotensin II in the hemodynamic response to unilateral obstructive uropathy.
    Moody TE; Vaughan ED; Wyker AT; Gillenwater JY
    Invest Urol; 1977 Mar; 14(5):390-7. PubMed ID: 845004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical usefulness of saralasin in human hypertension (author's transl)].
    Fouchard M; Bichara M; Grüfeld JP; Barbanel C; Meyer P; Funck-Brentano JL
    Nouv Presse Med; 1978 Feb; 7(7):539-43. PubMed ID: 643579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the renin-system in normo- and hypertension. Effect of angiotensin-inhibitor (1-sar-8-ala-angiotensin II) on the blood pressure of conscious or anaesthetized normal, nephrectomized and renal hypertensive rats.
    Bing J; Nielsen K
    Acta Pathol Microbiol Scand A; 1973 May; 81(3):254-62. PubMed ID: 4358386
    [No Abstract]   [Full Text] [Related]  

  • 24. [Variable action of central and peripheral angiotensin II blockade in genetic hypertension in rats].
    Mann JF; Phillips MI; Dietz R; Haebara H; Lüth JB; Ganten D
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():189-90. PubMed ID: 613564
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemodynamic effects of an angiotensin II antagonist in rabbits with perinephritis hypertension.
    Ichikawa S; Johnson JA; Stanton MW; Payne CG; Keitzer WF
    Proc Soc Exp Biol Med; 1977 Jun; 155(2):259-63. PubMed ID: 866354
    [No Abstract]   [Full Text] [Related]  

  • 26. [Renovascular hypertension: prediction of surgical treatment by angiotensin II blockade and saralasin (author's transl)].
    Mimran A; Deschodt G; Barjon P; Mary H; Thevenet A
    Nouv Presse Med; 1978 Dec; 7(43):3889-93. PubMed ID: 733540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The second Volhard Lecture: The use of blocking agents to define the functions of the renin--angiotensin system.
    Davis JO
    Clin Sci Mol Med Suppl; 1975 Jun; 2():3s-14s. PubMed ID: 802643
    [No Abstract]   [Full Text] [Related]  

  • 28. Intrarenal effects of the renin-angiotensin system.
    Ploth DW; Navar LG
    Fed Proc; 1979 Aug; 38(9):2280-5. PubMed ID: 456614
    [No Abstract]   [Full Text] [Related]  

  • 29. [Diagnostic and therapeutic significance of inhibitors of the renin-angiotensin system].
    Stumpe KO; Kolloch RE; Redlich B; Vetter H; Krück F
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():167-76. PubMed ID: 613561
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of renal factors in the pathogenesis of experimental hypertension.
    Koletsky S
    Int Rev Exp Pathol; 1973; 12():203-50. PubMed ID: 4349349
    [No Abstract]   [Full Text] [Related]  

  • 31. [Involvement of the Renin-angiotensin system in experimental hyper-tensions, demonstrated by a new specific angiotensin II antagonist].
    Schölkens BA
    Verh Dtsch Ges Kreislaufforsch; 1975; 41():320-7. PubMed ID: 1231333
    [No Abstract]   [Full Text] [Related]  

  • 32. Saralasin (1-sar-8-ala-angiotensin II): pharmacology and clinical use in angiotensin-dependent hypertension.
    Streeten DH; Castellian AW; Micalizzi ER; Dalakos TG; Anderson GH; Freiberg JM; Keenan RE
    Contrib Nephrol; 1976; 3():52-70. PubMed ID: 1026370
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of saralasin on plasma aldosterone in hypertensive man.
    Brown RD; Tucker R; Tue K; Wisgerhof M; Salassa R
    J Lab Clin Med; 1978 Mar; 91(3):473-9. PubMed ID: 627750
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A 100-year perspective on renal function and hypertension. Anti-renin therapy has made hypertensive renal failure a rarity].
    Bergström G; Herlitz H; Himmelmann A; Ljungman S; Aurell M
    Lakartidningen; 1999 Nov; 96(47):5209-14. PubMed ID: 10608112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypotensive action of an intra-nasally applied angiotensin II-antagonist.
    Schoelkens BA; Lux R; Steinbach R
    Arch Int Pharmacodyn Ther; 1977 Oct; 229(2):244-50. PubMed ID: 596979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Blood pressure behavior following 1-sar-8-ala-angiotensin II (saralasin) in essential and renovascular hypertension].
    Rosenthal J; Franz HE
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1305-7. PubMed ID: 1029984
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologic determinants and clinical applications of angiotensin II blockade in hypertensive disorders.
    Parra-Carrillo JZ; Baer L; Radichevich I
    Cardiovasc Clin; 1978; 9(1):183-95. PubMed ID: 667880
    [No Abstract]   [Full Text] [Related]  

  • 40. The place of renin in the mechanism of hypertension in chronic renal disease.
    Peart WS
    Clin Nephrol; 1975 Oct; 4(4):138-43. PubMed ID: 1104233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.